8-K: Nu Skin Enterprises Reports Q4 and Full-Year 2023 Results Slightly Above Guidance, Announces Dividend and Provides 2024 Outlook

Sentiment:

Quarterly Report


Nu Skin Enterprises announced fourth quarter and full-year 2023 results slightly above its latest guidance, while also updating capital allocation priorities and providing an initial outlook for 2024.

Worse than expectedThe company's revenue decreased by 6% in Q4 and 12% for the full year, indicating worse than expected performance.Customer numbers decreased by 15% and paid affiliates decreased by 30%, showing a decline in key metrics.The company's operating margin decreased, reflecting lower profitability.

Summary

  • Nu Skin Enterprises reported fourth quarter revenue of $488.6 million, a 6% decrease year-over-year, but slightly above guidance.
  • Rhyz revenue saw significant growth, increasing by 101% in the fourth quarter to $65.1 million and 41% for the full year to $216.6 million.
  • Full-year 2023 revenue was $1.97 billion, a 12% decrease compared to 2022, with a 3% negative impact from foreign exchange rates.
  • Earnings per share (EPS) for Q4 2023 were $0.15, or $0.37 excluding restructuring and other charges, compared to $1.15 or $0.89 excluding restructuring and impairment charges and a favorable tax rate in Q4 2022.
  • Full-year 2023 EPS was $0.17, or $1.85 excluding inventory write-off and other charges, compared to $2.07 or $2.90 excluding restructuring and impairment charges in 2022.
  • The company is rebalancing its dividend payout ratio to be in line with industry peers and will focus investments on Rhyz growth, new market expansion in India, and digital platform development.
  • Nu Skin's customer base decreased by 15% to 977,039, and paid affiliates decreased by 30% to 166,886, although this was partially due to an adjustment to eligibility requirements.
  • The company anticipates 2024 revenue between $1.73 and $1.87 billion, with EPS between $0.75 and $1.15, or $0.95 to $1.35 non-GAAP.
  • A quarterly cash dividend of $0.06 per share was declared, payable on March 6, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed results with some positives like Rhyz growth and a focus on future growth initiatives, but the overall tone is negative due to revenue declines, customer losses, and a challenging outlook. The company is clearly in a period of transition and facing headwinds.

Positives

  • The company's Q4 and full-year results were slightly above its latest guidance.
  • Rhyz business segment showed strong growth, with a 101% increase in revenue for Q4 and 41% for the full year.
  • Gross margin for the Nu Skin business improved to 77.4% in Q4 compared to 74.9% in the prior year.
  • The company is actively re-evaluating its capital allocation strategy to focus on long-term growth.
  • A new market expansion model is planned, starting with India in 2025.
  • The company is further developing its digital-first affiliate opportunity platform.

Negatives

  • Overall revenue decreased by 6% in Q4 and 12% for the full year compared to the previous year.
  • Customer numbers decreased by 15% and paid affiliates decreased by 30% year-over-year.
  • The company experienced a decrease in revenue in the Americas, South Korea, and Europe & Africa segments.
  • Operating margin decreased to 3.3% in Q4, or 6.4% excluding restructuring and other charges, compared to 5.3% or 8.8% excluding restructuring and impairment charges in the prior year.
  • The company anticipates a challenging global macro environment in the near term.

Risks

  • The company faces risks related to the macro-economic environment and disruptions associated with transforming its business.
  • There are risks associated with the direct selling laws and regulations in various markets, including the United States and Mainland China.
  • The company is exposed to competitive pressures in its markets.
  • There are risks related to accurately predicting and maintaining sufficient product quantities.
  • The company faces regulatory risks associated with its products.
  • The company is exposed to foreign currency fluctuations.

Future Outlook

The company anticipates a challenging global macro environment in the near term, improving throughout the year. They project 2024 revenue between $1.73 and $1.87 billion and EPS between $0.75 and $1.15, or $0.95 to $1.35 non-GAAP. A new market expansion model is planned, starting with India in 2025.

Management Comments

  • Ryan Napierski, Nu Skin president and CEO, stated that progress was impacted by macro-economic pressures and disruptions associated with transforming the business.
  • Napierski also mentioned the company is committed to generating long-term enterprise value by repositioning the company.
  • James D. Thomas, chief financial officer, stated that the initial 2024 guidance assumes the global macro environment remains challenging in the near-term, improving throughout the year.

Industry Context

The announcement reflects the challenges faced by direct selling companies in a changing economic environment, with a focus on digital transformation and new market expansion to drive future growth. The company's focus on the Rhyz ecosystem aligns with the trend of diversification and innovation in the beauty and wellness industries.

Comparison to Industry Standards

  • Nu Skin's revenue decline of 12% for the full year is worse than some of its peers in the beauty and wellness industry, such as Estee Lauder which reported a 10% decline in net sales for their fiscal year 2023.
  • The 41% growth in Rhyz revenue is a positive sign, indicating a successful diversification strategy, which is similar to other companies that have expanded into adjacent markets to drive growth.
  • The company's focus on digital transformation and new market expansion is in line with industry trends, as companies like L'Oreal and Unilever are also investing heavily in these areas.
  • The rebalancing of the dividend payout ratio to be in line with industry peers suggests that Nu Skin is aiming to align its capital allocation strategy with industry best practices, similar to how other mature companies in the sector manage their shareholder returns.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Scientific OfficerJoseph ChangN/AMarch 30, 2024Joseph Chang is stepping down from the role and it is no longer an executive officer position.

Stakeholder Impact

  • Shareholders will see a rebalancing of the dividend payout ratio and a focus on long-term growth initiatives.
  • Employees may experience changes due to the company's transformation and restructuring efforts.
  • Customers may see changes in product offerings and digital platforms.
  • Suppliers may be impacted by changes in the company's supply chain and product demand.
  • Creditors may be impacted by the company's financial performance and capital allocation decisions.

Next Steps

  • The company will focus on accelerating growth opportunities in Rhyz.
  • The company will facilitate a new market expansion model beginning with India in 2025.
  • The company will further the build-out of its digital-first affiliate opportunity platform.

Key Dates

DateDescription
February 9, 2024Joseph Chang informed Nu Skin that he will step down as Chief Scientific Officer as of March 30, 2024.
February 10, 2024The Board of Directors determined that the Chief Scientific Officer role is no longer an executive officer position.
February 14, 2024Nu Skin Enterprises issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2023.
February 26, 2024Shareholders of record date for the declared quarterly cash dividend.
February 28, 2024Replay of the webcast will be available until this date.
March 6, 2024Payment date for the declared quarterly cash dividend.
March 30, 2024Joseph Chang will step down from his role as Chief Scientific Officer.

Keywords

Nu Skin, Rhyz, Revenue, Earnings Per Share, Direct Selling, Beauty, Wellness, Dividend, Capital Allocation, Digital Platform, Market Expansion

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.